Your browser doesn't support javascript.
loading
Long-term efficacy and safety of apremilast in psoriatic arthritis: Focus on skin manifestations and special populations.
Balato, Anna; Campione, Elena; Cirillo, Teresa; Malara, Giovanna; Trifirò, Caterina; Bianchi, Luca; Fabbrocini, Gabriella.
Afiliación
  • Balato A; Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
  • Campione E; Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Cirillo T; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Malara G; Dermatology Unit, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy.
  • Trifirò C; Dermatology Unit, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy.
  • Bianchi L; Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Fabbrocini G; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Dermatol Ther ; 33(3): e13440, 2020 05.
Article en En | MEDLINE | ID: mdl-32306448
ABSTRACT
Few real-life studies evaluated long-term apremilast therapy in the variable spectrum of clinical-anamnestic features which can be found in psoriatic arthritis (PsA) patients. This real-life retrospective observational study aimed to assess long-term efficacy, safety, and tolerability of apremilast among patients with PsA and concomitant cutaneous psoriasis. A stratified analysis was performed on special populations, defined as (a) number (≤1 vs >2) of comorbidities, presence or absence of (b) history of malignancy, and (c) previous exposure to biologics. Patients attending three Italian University and Hospital centers, who received at least one dose of apremilast and had at least one follow-up visit were included. Ninety-six patients with PsA were identified. Psoriasis Area and Severity Index (PASI), Body Surface Area, 28-joint Disease Activity Score, and Dermatology Life Quality Index scores improved during treatment, already at week 4, relative to baseline. More than 2 comorbidities, history of malignancy and previous biologic treatment negatively influenced PASI responses. At least one adverse event was experienced by 56/96 patients, and 11/56 events required drug withdrawal. In conclusion, this study confirm efficacy and safety of apremilast on joints and skin involvement of PsA, highlighting which patients could have less favorable treatment response.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Artritis Psoriásica Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Artritis Psoriásica Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia